Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.58 |
| ▸ | CDK2 | P24941 | 16/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600613 | 1.00 | AKT1 (0.58) | AKT1CDK2ROCK1PIM1PIM3 | |
| SCHEMBL1600610 | 1.00 | AKT1 (0.58) | AKT1CDK2ROCK1PIM1PIM3 | |
| SCHEMBL1599811 | 0.88 | AKT1 (0.60) | AKT1CDK2PIM1PIM3 | |
| SCHEMBL1599807 | 0.88 | AKT1 (0.60) | AKT1CDK2PIM1PIM3 | |
| SCHEMBL1599805 | 0.88 | AKT1 (0.60) | AKT1CDK2PIM1PIM3 | |
| SCHEMBL1600679 | 0.88 | AKT1 (0.75) | AKT1CDK2 | |
| SCHEMBL1600675 | 0.88 | AKT1 (0.75) | AKT1CDK2 | |
| Trifluoroacetic Acid SCHEMBL1602118 | 0.84 | AKT1 (0.52) | AKT1CDK2PIM1PIM3PIM2 | |
| Trifluoroacetic Acid SCHEMBL1602115 | 0.84 | AKT1 (0.52) | AKT1CDK2PIM1PIM3PIM2 | |
| SCHEMBL1601939 | 0.83 | AKT1 (0.64) | AKT1CDK2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | claimed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | claimed |
| EP-1809282-B1 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7919514-B2 | Protein kinase B inhibitors; anticarcinogenic, antiinflammatory and antiproliferative agents; metabolic disorders; 3-(3-fluoro-phenyl)-N-[5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-yl]-propane-1,2-diamine and derivatives | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7700636-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | AKT1 23/4885CDK2 124/4885ROCK1 726/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | AKT1 23/4885CDK2 124/4885ROCK1 726/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | AKT1 23/4885CDK2 124/4885ROCK1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.